BINDING OF 9-CIS-RETINOIC ACID AND ALL-TRANS-RETINOIC ACID TO RETINOIC ACID RECEPTOR-ALPHA, RECEPTOR-BETA, AND RECEPTOR-GAMMA - RETINOIC ACID RECEPTOR-GAMMA BINDS ALL-TRANS-RETINOIC ACID PREFERENTIALLY OVER 9-CIS-RETINOIC ACID

被引:0
作者
ALLENBY, G [1 ]
JANOCHA, R [1 ]
KAZMER, S [1 ]
SPECK, J [1 ]
GRIPPO, JF [1 ]
LEVIN, AA [1 ]
机构
[1] HOFFMANN LA ROCHE INC,DEPT TOXICOL & PATHOL,NUTLEY,NJ 07110
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Both 9-cis-retinoic acid (RA) and all-trans-RA (t-RA) compete for [H-3]9-cis-RA binding to RA receptors (RAR alpha, beta, and gamma) in nucleosol fractions from transiently transfected COS-1 cells with IC50 values of approximately 12 and 5 nM, respectively. Curiously, 9-cis-RA competes for [H-3]t-RA binding to mouse RAR alpha, beta, and gamma with IC50 values of 31, 8, and 60 nM, respectively, while t-RA itself does not exhibit such differential competition (IC50 values for RARs, 5 nM). A similar pattern is observed with human retinoic acid receptors (RARs). Differential binding of 9-cis-RA to the RAR beta and gamma receptors is also found following in vitro transcription and translation of these receptors. Displacement assays demonstrate that t-RA exhibits similar off-rates for RAR alpha, beta, and gamma. However, 9-cis-RA is 6-fold more rapidly displaced from RAR gamma than from RAR beta. When RAR-transfected COS-1 cells are incubated with [H-3]t-RA, [H-3]-9-cis-RA or various mixtures of these two radioligands, high performance liquid chromatography analysis demonstrates that the ligands bound in nucleosol fractions from RAR beta-transfected cells reflect the isomer content of the media. However, in identical whole cell assays, nucleosol fractions from RAR gamma-transfected cells preferentially bind t-RA over 9-cis-RA, consistent with the in vitro data. These binding kinetics in vitro and in whole cells suggest that there could be differences in the interactions of the receptor subtypes with the endogenous retinoic acids under physiologic conditions.
引用
收藏
页码:16689 / 16695
页数:7
相关论文
共 45 条
[1]   RETINOIC ACID RECEPTORS AND RETINOID X-RECEPTORS - INTERACTIONS WITH ENDOGENOUS RETINOIC ACIDS [J].
ALLENBY, G ;
BOCQUEL, MT ;
SAUNDERS, M ;
KAZMER, S ;
SPECK, J ;
ROSENBERGER, M ;
LOVEY, A ;
KASTNER, P ;
GRIPPO, JF ;
CHAMBON, P ;
LEVIN, AA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (01) :30-34
[2]   A RETINOIC ACID RECEPTOR-ALPHA ANTAGONIST SELECTIVELY COUNTERACTS RETINOIC ACID EFFECTS [J].
APFEL, C ;
BAUER, F ;
CRETTAZ, M ;
FORNI, L ;
KAMBER, M ;
KAUFMANN, F ;
LEMOTTE, P ;
PIRSON, W ;
KLAUS, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (15) :7129-7133
[3]   RETINOIC ACID AND SYNTHETIC ANALOGS DIFFERENTIALLY ACTIVATE RETINOIC ACID RECEPTOR DEPENDENT TRANSCRIPTION [J].
ASTROM, A ;
PETTERSSON, U ;
KRUST, A ;
CHAMBON, P ;
VOORHEES, JJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 173 (01) :339-345
[4]   IDENTIFICATION OF SYNTHETIC RETINOIDS WITH SELECTIVITY FOR HUMAN NUCLEAR RETINOIC ACID RECEPTOR-GAMMA [J].
BERNARD, BA ;
BERNARDON, JM ;
DELESCLUSE, C ;
MARTIN, B ;
LENOIR, MC ;
MAIGNAN, J ;
CHARPENTIER, B ;
PILGRIM, WR ;
REICHERT, U ;
SHROOT, B .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 186 (02) :977-983
[5]   IDENTIFICATION OF A 2ND HUMAN RETINOIC ACID RECEPTOR [J].
BRAND, N ;
PETKOVICH, M ;
KRUST, A ;
CHAMBON, P ;
DETHE, H ;
MARCHIO, A ;
TIOLLAIS, P ;
DEJEAN, A .
NATURE, 1988, 332 (6167) :850-853
[6]  
CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10
[7]  
Chin W.W., 1991, NUCL HORMONE RECEPTO, P79
[8]   LIGAND SPECIFICITIES OF RECOMBINANT RETINOIC ACID RECEPTORS RAR-ALPHA AND RAR-BETA [J].
CRETTAZ, M ;
BARON, A ;
SIEGENTHALER, G ;
HUNZIKER, W .
BIOCHEMICAL JOURNAL, 1990, 272 (02) :391-397
[9]   SIMULTANEOUS ANALYSIS OF FAMILIES OF SIGMOIDAL CURVES - APPLICATION TO BIOASSAY, RADIOLIGAND ASSAY, AND PHYSIOLOGICAL DOSE-RESPONSE CURVES [J].
DELEAN, A ;
MUNSON, PJ ;
RODBARD, D .
AMERICAN JOURNAL OF PHYSIOLOGY, 1978, 235 (02) :E97-E102
[10]  
DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556